CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Dostarlimab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05751629
NCT05751629Phase 2Completed
CompareCT.gov

Cohort A: PARP Inhibitor-Naïve Platinum-Resistant Ovarian Cancer Treatment Cohort With TSR-042, Bevacizumab, and Niraparib

Tesaro, Inc.·interventional·Posted Mar 2, 2023·Updated Apr 21, 2023

In Brief

A Phase 2 clinical trial evaluating Dostarlimab, Bevacizumab, and 1 other intervention for Ovarian Neoplasm. Completed, enrolled 41 participants across 10 sites.

Detailed Summary

The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease. This study is a sub study of the master protocol - OPAL (NCT03574779).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 2, 2023
Enrollment StartNov 15, 2018
Primary CompletionApr 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 3.3 years ago

Interventions

Dostarlimabdrug

Dostarlimab was administered.

Bevacizumabdrug

Bevacizumab was administered.

Niraparibdrug

Niraparib was administered.